Institutional members access full text with Ovid®

Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results

Lacombe, Karinea,b,c; Valin, Nadiab; Stitou, Hindd; Gozlan, Joële; Thibault, Vincentf; Boyd, Andersc; Poirier, Jean-Marieg; Meynard, Jean-Lucb; Valantin, Marc-Antoined,h; Bottero, Juliea,b,c; Girard, Pierre-Mariea,b,c

doi: 10.1097/QAD.0b013e32836138d0
Research letters

The efficacy and tolerance of telaprevir (TVR) was examined in 20 mostly cirrhotic HIV-hepatitis C genotype 1 (HCV-G1)-infected patients failing previous treatment with pegylated-interferon and ribavirin (PR). HCV-RNA less than 12 IU/ml was observed in 35.3% of patients at W2, 55.0% at W4, 65.0% at W12 and 55.0% at W24. All patients with virological failure (n = 9) exhibited V36M/R155K mutations. Early virological response was a determinant of HCV-RNA less than 12 IU/ml at W24 (P < 0.001). No grade 3–4 dermatological side-effects were reported. TVR-PR tritherapy appeared to be rather effective and well tolerated among difficult-to-treat HIV-HCV-G1 patients.

aUniversité Pierre et Marie Curie

bService de Maladies Infectieuses et Tropicales, Hôpitaux Universitaires de l’Est Parisien, Hôpital Saint-Antoine

cInserm UMR-S707

dService de Maladies Infectieuses et Tropicales, Groupe Hospitalier Pitié-Salpêtrière

eService de Bactériologie-Virologie, Hôpitaux Universitaires de l’Est Parisien, Hôpital Saint-Antoine

fService de Bactériologie-Virologie, Groupe Hospitalier Pitié-Salpêtrière

gService de Pharmacologie, Hôpitaux Universitaires de l’Est Parisien, Hôpital Saint-Antoine

hInserm UMR-S943, Paris, France.

Correspondence to Dr Karine Lacombe, MD, PhD, Service de Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, 184 rue du Fbg Saint-Antoine, 75012 Paris, France. Tel: +33 1 49283137; fax: +33 1 49282149; e-mail: karine.lacombe@sat.aphp.fr

Received 23 January, 2013

Revised 13 March, 2013

Accepted 13 March, 2013

© 2013 Lippincott Williams & Wilkins, Inc.